BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CRISPR Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies CRISPR Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05329649-10277@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053296
 49)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Safety and Efficacy of CTX001 in Pediatric Part
 icipants With Severe Sickle Cell Disease (SCD)\nEstimated primary completi
 on: 6 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exag
 amglogene-autotemcel-casgevy#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05329649
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477563-10277@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT054775
 63)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Efficacy and Safety of a Single Dose of CTX001 
 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickl
 e Cell Disease\nEstimated primary completion: 9 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0547756
 3
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05356195-10277@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053561
 95)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3.\nStudy: Evaluatio
 n of Safety and Efficacy of CTX001 in Pediatric Participants With Transfus
 ion-Dependent β-Thalassemia (TDT)\nEstimated primary completion: 14 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exagamgloge
 ne-autotemcel-casgevy#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05356195
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318155-1143@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SRSD107: Phase 2 readout est. (NCT07318155)
DESCRIPTION:SRSD107\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study of SRSD107 in Participants With Chronic Coronary and/or Perip
 heral Arterial Disease\nEstimated primary completion: December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/srsd107#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07318155
URL:https://assetmemo.bio/drug/srsd107#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804004-5691@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Zugocabtagene geleucel: Phase 1/2 readout est. (NCT07804004)
DESCRIPTION:Zugocabtagene geleucel\, phase 1/2.\nStudy: A Safety and Effica
 cy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmu
 ne Disease\nEstimated primary completion: 30 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07804004
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05643742-5691@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Zugocabtagene geleucel: Phase 1/2 readout est. (NCT05643742)
DESCRIPTION:Zugocabtagene geleucel\, phase 1/2\, Follicular Lymphoma.\nStud
 y: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed
  or Refractory B-Cell Malignancies\nEstimated primary completion: January 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/zugocabtagene-g
 eleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05643742
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549698-5691@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Zugocabtagene geleucel: Phase 1/2 readout est. (NCT07549698)
DESCRIPTION:Zugocabtagene geleucel\, phase 1/2.\nStudy: Safety and Prelimin
 ary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hema
 tologic Autoimmune Disease\nEstimated primary completion: December 2033. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zugocabtagene-geleucel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 49698
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208529-10277@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20390930
DTEND;VALUE=DATE:20391001
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT042085
 29)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: A Long-term Follow-up Study in Participants Who Received CTX0
 01\nEstimated primary completion: 30 September 2039. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04208529
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
